Radiopharmaceuticals

• Radiopharmaceuticals are a class of targeted therapeutics that deliver radioactive isotopes directly to cancer cells. These agents combine a biologically active targeting molecule — such as a peptide, antibody, or small molecule — with a radioisotope that emits ionizing radiation. Once bound to its target, the radiopharmaceutical delivers localized radiation to kill tumor cells with high precision while minimizing damage to surrounding healthy tissue.
• Radiopharmaceuticals are increasingly being used in both diagnostic imaging (e.g., PET, SPECT) and therapeutic applications (e.g., targeted alpha and beta therapies), making them a powerful tool in precision oncology.

A strategic alliance for innovation in radiopharmaceuticals
Together, Crown Bioscience and Medicines Discovery Catapult (MDC) are building an integrated ecosystem for radiopharmaceutical innovation, bridging discovery, imaging, pharmacology, and translational models to support oncology drug developers.